For patients receiving PD-L1 inhibitors, a significant association was observed between low level of CRABP2 and poor PFS in all patients and esophageal adenocarcinoma patients, but no association with OS was found. This evidence concerns the gene CRABP2 and esophageal adenocarcinoma.